Unosi

• Efficacy and Safety of Once Monthly Ibandronate Treatment in Patients with Reduced Bone Mineral Density - ESTHER Study (2010)

  N. Vujasinović Stupar, N. Milić, L. Petrović Lackov, N. Prodanović, M. Mijailović Ivković, Z. Grujić, Efficacy and Safety of Once Monthly Ibandronate Treatment in Patients with Reduced Bone Mineral Density - ESTHER Study, SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, Vol. 138, No. 1-2, pp. 56 - 61, 2010

• Parathyroid Hormone Response to Vitamin D Insufficiency in Elderly Males With Chronic Heart Failure (2011)

  B. Božić, G. Lončar, N. Prodanović, T. Lepić, Z. Radojčić, V. Čvorović, S. Dimković, B. Popović, Parathyroid Hormone Response to Vitamin D Insufficiency in Elderly Males With Chronic Heart Failure, Physiological research , pp. 155 - 163, 2011

• Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure (2011)

  G. Lončar, B. Božić, S. Dimković, N. Prodanović, Z. Radojčić, V. Čvorović, Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure, JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, pp. 78 - 85, 2011

• Relationship of reduced cerebral blood flow and heart failure severity in elderly males (2011)

  G. Lončar, B. Božić, S. Dimković, N. Prodanović, Z. Radojčić, V. Čvorović, Relationship of reduced cerebral blood flow and heart failure severity in elderly males, AGING MALE, pp. 59 - 65, 2011

• A potential cross-talk between fat and bone in patients with chronic heart failure (2011)

  G. Lončar, B. Božić, N. Prodanović, Z. Radojčić, N. Čvorović, S. Dimković, V. Popović, A potential cross-talk between fat and bone in patients with chronic heart failure, EUROPEAN HEART JOURNAL, pp. 32 - 609, 2011

• Digital clubbing as an unusual comlication of the secondary hyperparathyroidism associated atypical neutrophils: a case report (2012)

  N. Prodanović, Z. Špirić, G. Trninić, M. Erić, Digital clubbing as an unusual comlication of the secondary hyperparathyroidism associated atypical neutrophils: a case report, EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, pp. 98 - 102, 2012

• Association od adiponetic with peripheral muscle status in elderly patients with heart failure (2013)

  G. Lončar, B. Božić, S. Healing, N. Prodanović, V. Popović-Brkić, Association od adiponetic with peripheral muscle status in elderly patients with heart failure, EUROPEAN JOURNAL OF INTERNAL MEDICINE, pp. 10 - 10, 2013

• A randomised,double-blind,parallel-group study to dmostrate eqivalence in afficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:The PLANETRA study (2013-05)

  D. Yoo, P. Hrycaj, P. Miranda, E. Ramiterre, M. Piotrowski, S. Shevchuk, V. Kovalenko, N. Prodanović, M. Abello-Banfi, S. Gutierrez-Ureña, L. Morales-Olazabal, M. Tee, R. Jimenez, O. Zamani, S. Lee, H. Kim, W. Park, U. Müller-Ladner, A randomised,double-blind,parallel-group study to dmostrate eqivalence in afficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis:The PLANETRA study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, May, 2013

• 1. Osteoporoza u inflamatornim bolestima creva (2013-05)

  N. Prodanović, 1. Osteoporoza u inflamatornim bolestima creva, STED Journal, Vol. 39, No. 1, pp. 149 - 156, May, 2013

• FRI0281 The Rate of Positive Conversion in the Quantiferon- TB Gold Test over 2 Years among Patients Treated with CT-P13 or Innovator Infliximab in the Extension Studies of Planetas and Planetra (2014)

  P. Wonung, D. Yoo, P. Hrycaj, N. Prodanović, S. Lee, FRI0281 The Rate of Positive Conversion in the Quantiferon- TB Gold Test over 2 Years among Patients Treated with CT-P13 or Innovator Infliximab in the Extension Studies of Planetas and Planetra, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2014

• FRI0143 A radomized, double-blind, phase 3 study demonstrates clinical equivalence od CT-P13 to ifliximab when co-administered with methotrexate in patients with active rheumatoid arthritis (2014)

  D. Yoo, P. Hrycaj, P. Miranda, E. Piotrowski, S. Shevchuk, V. Kovalenko, N. Prodanović, M. Abello-Banfi, S. Gutierrez-Ureña, L. Morales-Olazabal, M. Tee, R. Jimenez, O. Zamani, S. Lee, H. Kim, W. Park, U. Müller-Ladner, FRI0143 A radomized, double-blind, phase 3 study demonstrates clinical equivalence od CT-P13 to ifliximab when co-administered with methotrexate in patients with active rheumatoid arthritis, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2014

• The Serbian Sokol club in Banja Luka (2015)

  M. Prodanović, P. Pavlović, The Serbian Sokol club in Banja Luka, Physical Education and Sport through the centuries, Vol. 2, No. 1, pp. 32 - 53, 2015

• BONE MARKERS IN MONITORING OF ANTIRESORPTIVE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS PATIENTS (2015)

  T. Đopalić, N. Prodanović, B. Božić, BONE MARKERS IN MONITORING OF ANTIRESORPTIVE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS PATIENTS, Acta medica Medianae, Vol. 54, No. 3, pp. 5 - 11, 2015

• SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (2015-06)

  J. Choe, N. Prodanović, j. Niebrizidovski, i. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zielinska, J. Choe, Y. Rho, J. Smolen, SAT0152 A Randomised,Doble-Blind ,Phase III Study Comparing SB2,An Infliximab Biosimilar, To the Infliximab Reference Product (Remicade) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, Jun, 2015

• FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud (2016)

  J. Smolen, J. Choe, N. Prodanović, I. Staykov, E. Dokoupilova, A. Baranauskaite, R. Yatsyshyn, M. Mekić, W. Porawska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, Z. Lee, Y. Rho, FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2016

• Efficacy and safety of CT- P13 (biosimilar infliximab) in patients with rheumatoid arthritis :Comparison betwen switching from reference infliximab to CT-P13 and continuing CT- P13 in the PLANETRA extension study (2016)

  D. Yoo, N. Prodanović, J. Jaworski, P. Miranda, E. Ramiterre, A. Lanzon, A. Baranauskaite, P. Wiland, C. Abud-Mendoza, B. Oparanov, S. Smiyan, H. Kim, S. Lee, S. Kim, W. Park, Efficacy and safety of CT- P13 (biosimilar infliximab) in patients with rheumatoid arthritis :Comparison betwen switching from reference infliximab to CT-P13 and continuing CT- P13 in the PLANETRA extension study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2016

• Skeletal muscle status and its prognostic role in men with heart failure with reduced ejection fraction (Meeting Abstract) (2016)

  G. Lončar, B. Božić, S. Healing, N. Prodanović, V. Popović-Brkić, Skeletal muscle status and its prognostic role in men with heart failure with reduced ejection fraction (Meeting Abstract), EUROPEAN HEART JOURNAL, pp. 10 - 10, 2016

• 3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study (2017)

  J. Smolen, J. Choe, N. Prodanović, Y. Rho, 3. Safety, immunogenecity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis:Results of a randomised, double-blind, phase III transation study, ANNALS OF THE RHEUMATIC DISEASES, pp. 10 - 10, 2017

• Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results (2017)

  J. Smolen, J. Choe, N. Prodanović, J. Niebrizidovski, I. Staikov, E. Dokoupilova, A. Baranauskaite, R. Iatsishin, M. Mekić, V. Poravska, H. Ciferska, K. Jedrichovicz-Rosiak, A. Zelinska, I. Lee, I. Rho, Comparing biosimilar SB2 with reference infiximab after 54 weeks of a double-bilind trail:Clinical, structural and safety results, RHEUMATOLOGY, pp. 10 - 10, 2017

• Androgen status in non-diabetic elderly men with heart failure (2017)

  G. Lončar, B. Božić, A. N, S. Nešković, N. Prodanović, V. Popović-Brkić, Androgen status in non-diabetic elderly men with heart failure, AGING MALE, pp. 10 - 10, 2017